head and neck cancer

Swallowing Outcomes Following Early Treatment of Head and Neck Cancer-Related Lymphedema

By MedXY 10/27/2026

Early intervention for head and neck cancer-related lymphedema significantly improves swallowing function and patient-reported outcomes, supporting timely multidisciplinary care.

Clinical Updates news Oncology Radiology

Integrating Body Composition Metrics for Prognostication in Head and Neck Cancer Radiotherapy: Advances and Clinical Implications

By MedXY 10/22/2026

Recent evidence highlights the prognostic significance of body composition metrics, including BMI, skeletal muscle mass, and adiposity distribution, in head and neck cancer radiotherapy outcomes. Automated 3D CT phenotyping refines risk stratification to guide individualized supportive care.

Anesthesiology Clinical Updates news Plastic Surgery

Cannabis Use and Prolonged Opioid Utilization After Head and Neck Free Flap Reconstructive Surgery: A Clinical Evidence Synthesis

By MedXY 10/20/2026

This review evaluates evidence linking perioperative cannabis use to prolonged opioid use and functional outcomes in head and neck cancer patients undergoing free flap reconstruction, emphasizing implications for pain management.

news Oncology Otorhinolaryngology

Wildfire Air Pollution Exposure and Head and Neck Cancer Incidence

By MedXY 10/18/2026

This study identifies a link between exposure to wildfire-specific PM2.5 air pollution and increased risks of head and neck cancers over a 10-year period, with notable effects on oral cavity, oropharyngeal, and laryngeal cancers.

news Oncology Otorhinolaryngology

Long-Term Opioid Use After Radiation Therapy in Head and Neck Cancer: Prevalence, Risk Factors, and Clinical Implications

By MedXY 10/06/2026

A study at The Ohio State Comprehensive Cancer Center reveals high rates of prolonged opioid use following radiation or chemoradiation in head and neck cancer patients, underscoring the need for tailored opioid stewardship.

news Oncology Otorhinolaryngology

EHR-Integrated Synoptic Operative Reporting: Enhancing Documentation in Head and Neck Oncologic Surgery

By MedXY 09/26/2026

This study evaluates the development, implementation, and performance of EHR-integrated synoptic operative reporting templates in head and neck cancer surgery, highlighting improved documentation quality and variable adherence.

news Oncology Otorhinolaryngology

Immunotherapy in Head and Neck Squamous Cell Carcinoma with Low PD-L1 Expression: A Meta-Analytic Insight into Survival Outcomes

By MedXY 09/21/2026

A meta-analysis reveals immune checkpoint inhibitors may reduce survival in head and neck squamous cell carcinoma patients with PD-L1 combined positive scores less than 1, signaling caution in this subgroup's treatment.

news Oncology Otorhinolaryngology

Enhancing Care for Head and Neck Cancer Patients: Insights from a Novel Subspecialty Outpatient Palliative Medicine Clinic

By MedXY 09/03/2026

A surgeon-led outpatient palliative care clinic for head and neck cancer patients demonstrated significant symptom improvement, prolonged survival, and high rates of home or hospice deaths, underscoring its value in multidisciplinary cancer care.

news Oncology Otorhinolaryngology

MDADI Composite Score Thresholds for Efficient Screening of Swallowing Impairment in Head and Neck Cancer Patients

By MedXY 08/27/2026

This study validates the MD Anderson Dysphagia Inventory (MDADI) as a reliable screening tool for VFSS-graded swallowing impairment in head and neck cancer patients and proposes a concise four-item version to optimize clinical utility.

news Oncology Otorhinolaryngology

Enhanced Pathologic Responses with Neoadjuvant Chemoimmunotherapy in Resectable Head and Neck Squamous Cell Carcinoma

By MedXY 08/24/2026

Neoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.

news Oncology Otorhinolaryngology

Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer

By MedXY 08/21/2026

A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.

news Oncology Otorhinolaryngology

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

By MedXY 08/11/2026

The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.

Clinical Updates news Oncology Otorhinolaryngology

Patient Perceptions of Telehealth Use in Head and Neck Cancer Surveillance: A Qualitative Synthesis

By MedXY 08/02/2026

This review synthesizes evidence on patients' perceptions of telehealth for head and neck cancer surveillance, highlighting barriers, benefits, and the potential of hybrid models to improve acceptability post-treatment.

news Oncology Otorhinolaryngology

Elevated Blood Manganese Linked to Increased Risk of Head and Neck Squamous Cell Carcinomas: Insights from Mendelian Randomization

By MedXY 07/05/2026

A genetic study reveals that higher blood manganese levels are significantly associated with increased risks of oral cavity and HPV-positive oropharyngeal squamous cell carcinomas, suggesting a novel biomarker and potential target for prevention strategies in head and neck cancers.

Clinical Updates news Otorhinolaryngology Radiology

Addressing Barriers and Enhancing Facilitators of Timely Postoperative Radiotherapy for Head and Neck Cancer in Rural Communities: A Clinical Review

By MedXY 07/02/2026

This review synthesizes evidence on factors influencing delays in postoperative radiotherapy for head and neck cancer in rural settings, emphasizing communication, coordination, and community resources to inform strategies that improve care equity and outcomes.

news Oncology Otorhinolaryngology

MDASI-HN Symptom Profiling for Early Risk Stratification of Hypoglossal Neuropathy in Oropharyngeal Cancer Survivors

By MedXY 06/18/2026

This study found that patient-reported speech/voice and related head-and-neck symptoms can help predict hypoglossal neuropathy risk after oropharyngeal cancer treatment, supporting earlier surveillance with the MDASI-HN-NERVE score.

news Oncology Otorhinolaryngology

Area-Level Socioeconomic Disadvantage Is Linked to Worse Pretreatment Head and Neck Cancer–Specific Quality of Life

By MedXY 06/08/2026

In patients with head and neck cancer, living in the most socioeconomically disadvantaged areas was associated with poorer pretreatment head and neck cancer–specific quality of life, while associations with other quality-of-life domains were small and not clinically meaningful.

Internal Medicine news Otorhinolaryngology

Routine Hospitalist Co-Management After Head and Neck Free Flap Surgery Was Linked to Fewer Escalations of Care, but Not Shorter Stay or Lower Mortality

By MedXY 06/06/2026

In a retrospective cohort of 362 head and neck free tissue transfer patients, routine hospitalist involvement was associated with fewer transfers to a higher level of care, without significant effects on length of stay, readmission, or 90-day mortality.

news Oncology Pathology & Lab Medicine/Bệnh học

Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer

By MedXY 05/20/2026

In advanced head and neck squamous cell carcinoma, pretreatment weight loss and low prognostic nutritional index were linked to shorter progression-free survival after immunotherapy, while baseline BMI was not predictive.

news Oncology Otorhinolaryngology

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer

By MedXY 04/27/2026

A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific comorbidities.